Screener
Alnylam Pharmaceuticals ALNY Comprehensive Income (Loss), Net of Tax, Attributable to Parent
Comprehensive Income (Loss), Net of Tax, Attributable to Parent at other companies
Other financials
Where this comes from
Reported directly by Alnylam Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:ComprehensiveIncomeNetOfTax.
The source filing: Alnylam Pharmaceuticals’s 10-Q, filed July 30, 2026.
- Filed
- Jul 30, 2026, 8:11 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001178670-26-000062
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Statements of Comprehensive Income (Loss) | ||||
| Net income (loss) | $164,494 | $(72,228) | $370,485 | $(90,479) |
| Other comprehensive (loss) income: | ||||
| Unrealized (losses) gains on marketable securities | (3,635) | (343) | (7,287) | 687 |
| Foreign currency translation (losses) gains | (3,698) | 7,855 | (4,932) | 3,771 |
| Defined benefit pension plans, net of tax | 89 | 53 | 178 | 108 |
| Total other comprehensive (loss) income | (7,244) | 7,565 | (12,041) | 4,566 |
| Comprehensive income (loss) | $157,250 | $(64,663) | $358,444 | $(85,913) |
Cover / Front Matter
FAQ
- What is Alnylam Pharmaceuticals's comprehensive income (loss), net of tax, attributable to parent?
- Alnylam Pharmaceuticals (ALNY) reported comprehensive income (loss), net of tax, attributable to parent of $157.25M in Q2 2026.
- How has Alnylam Pharmaceuticals's comprehensive income (loss), net of tax, attributable to parent changed year-over-year?
- Alnylam Pharmaceuticals's comprehensive income (loss), net of tax, attributable to parent increased by 367.8% year-over-year, from -$58.71M to $157.25M.
- What is the long-term trend for Alnylam Pharmaceuticals's comprehensive income (loss), net of tax, attributable to parent?
- Over 4 years (2021 to 2025), Alnylam Pharmaceuticals's comprehensive income (loss), net of tax, attributable to parent has grown at a -23.2% compound annual growth rate (CAGR), from -$842.46M to $292.52M.
- What does comprehensive income (loss), net of tax, attributable to parent mean?
- This metric represents the total change in equity from non-owner sources, encompassing net income plus other comprehensive income items such as unrealized gains or losses on securities and foreign currency translation adjustments. It provides a more holistic view of the company's financial performance beyond traditional net income by including volatile, non-operating valuation changes. Investors use this to assess the total economic impact of all financial activities on the company's net worth.
Ask your AI about Alnylam Pharmaceuticals's comprehensive income (loss), net of tax, attributable to parent.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude